Stocks Health care GILD
NASDAQ · Health careGilead Sciences, Inc. (GILD)
Gilead Sciences, Inc. brought in $30.5B of revenue over the twelve months to June 30, 2026, up 5.5% from a year earlier. It posted a net loss of $3.2B. Operating cash flow minus capital spending left $9.5B of free cash flow in fiscal 2025. At June 30, 2026 it held $3.2B in cash against $26.2B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Gilead Sciences, Inc.
- Net worth
- Gilead Sciences, Inc. has a market value (market cap) of $186.5B at the latest share price, and shareholders' equity of $11.8B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $29.4B (+2.4% year on year), with net income of $8.5B. Over the 12 months to June 30, 2026: revenue $30.5B, net loss $3.2B.
- Cash flow
- In fiscal 2025 operations brought in $10B of cash; after $563M of capital spending, free cash flow was $9.5B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Gilead Sciences, Inc.'s next report is expected around October 29, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Gilead Sciences, Inc. declared dividends of $3.16 per share in fiscal 2025, a yield of 2.10% at the current price.
What Gilead Sciences, Inc. does
Gilead Sciences discovers, develops, and commercializes medicines for life-threatening diseases. It produces antiviral therapies used in the treatment and prevention of HIV and hepatitis B and C, as well as oncology and cell therapy treatments. Its products are purchased by pharmacies, hospitals, wholesale distributors, and healthcare providers. Its shares trade on NASDAQ under the ticker GILD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $29.4B | $8.5B | $6.78 | $9.5B |
| 2024 | $28.8B | $480M | $0.38 | $10.3B |
| 2023 | $27.1B | $5.7B | $4.50 | $7.4B |
| 2022 | $27.3B | $4.6B | $3.64 | $8.3B |
| 2021 | $27.3B | $6.2B | $4.93 | $10.8B |
| 2020 | $24.7B | $123M | $0.10 | $7.5B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where GILD ranks in Health care
Dividends
Gilead Sciences, Inc. declared $3.16 per share in fiscal 2025. At the current price that is a yield of 2.10%. It paid out $4B in cash dividends, 47% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $3.16 | $4B | 47% |
| 2024 | $3.08 | $3.9B | 816% |
| 2023 | $3.00 | $3.8B | 67% |
| 2022 | $2.92 | $3.7B | 81% |
| 2021 | $2.84 | $3.6B | 58% |
| 2020 | $2.72 | $3.4B | 2,804% |
Latest SEC filings
What Gilead Sciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 26, 2026Form N-PX filing N-PX
- August 7, 2026Activist stake changed SCHEDULE 13D/A
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 10% to $7.8B versus the same quarter last year; diluted EPS -$8.45 versus $1.56.
- August 4, 2026
- August 3, 2026Form 13F-HR filing 13F-HR
- May 27, 2026Activist stake changed SCHEDULE 13D/A
- May 20, 2026
- May 8, 2026Form 13F-HR filing 13F-HR
- May 7, 2026
What is GILD worth? A DCF from its reported cash flow
Insider trades
What the people running Gilead Sciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $15.7M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | O'Day Daniel PatrickChairman & CEO, Director | Soldpre-planned (10b5-1) | 12,000 | $1.8M |
| October 1, 2026 | O'Day Daniel PatrickChairman & CEO, Director | Soldpre-planned (10b5-1) | 3,000 | $445.9K |
| September 22, 2026 | Burkhart ErinSVP, Controllership | Exercised options | 2,223 | - |
| September 22, 2026 | Burkhart ErinSVP, Controllership | Shares withheld for tax | 768 | $117.3K |
| September 15, 2026 | Dickinson Andrew DChief Financial Officer | Soldpre-planned (10b5-1) | 3,000 | $435.9K |
| September 15, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Soldpre-planned (10b5-1) | 1,600 | $229.9K |
| September 15, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Soldpre-planned (10b5-1) | 800 | $115.6K |
| September 15, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Soldpre-planned (10b5-1) | 600 | $87.2K |
Who owns GILD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Gilead Sciences, Inc.13D, may seek influence | 24.7% | August 7, 2026 |
| Vanguard Capital Management13G, passive | 7.51% | April 29, 2026 |
| Fmr LLC13G, passive with 1 related filers | 5.3% | February 5, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 2,305 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 138,260,357 | +4,022,909 |
| Vanguard Capital Management LLC | 84,980,080 | +468,579 |
| Fmr LLC | 70,920,573 | -2,150,969 |
| State Street Corp | 67,246,036 | +1,974,550 |
| Capital World Investors | 40,988,975 | -294,958 |
| Invesco Ltd. | 40,664,384 | -1,737,259 |
| Vanguard Portfolio Management LLC | 39,791,696 | +390,175 |
| Geode Capital Management, LLC | 32,514,391 | +535,972 |
| Morgan Stanley | 24,800,266 | +387,445 |
| Dodge & Cox | 23,677,567 | -573,259 |
| Norges Bank | 21,965,555 | new |
| Jpmorgan Chase & Co | 21,238,864 | -12,834,363 |
| Capital Research Global Investors | 19,393,296 | -7,734,237 |
| Bank of America Corp | 19,484,569 | -1,140,435 |
| Bank of New York Mellon Corp | 15,806,938 | +242,621 |
| Wellington Management Group Llp | 18,595,131 | -1,032,376 |
| Northern Trust Corp | 14,760,533 | +99,849 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 13,140,989 | -216,406 |
| Goldman Sachs Group Inc | 12,165,860 | +100,860 |
| Legal & General Group Plc | 10,612,691 | -40,848 |
Insiders
15 insiders reported holding 1,012,532 shares in total, about $152.3M at the last price.
| Holder | Shares |
|---|---|
| O'Day Daniel PatrickChairman & CEO, Director | 566,683 |
| Dickinson Andrew DChief Financial Officer | 164,096 |
| Mercier JohannaChief Comm & Corp Aff Officer | 116,684 |
| Telman Deborah HEVP, Corporate Affairs & GC | 43,676 |
| Barton Jacqueline KDirector | 27,202 |
| Berger DietmarChief Medical Officer | 19,522 |
| Manwani HarishDirector | 15,015 |
| Rodriguez JavierDirector | 13,364 |
| Welters AnthonyDirector | 12,894 |
| Bluestone JeffreyDirector | 10,066 |
Questions about GILD
What does Gilead Sciences, Inc. do?
Gilead Sciences discovers, develops, and commercializes medicines for life-threatening diseases. It produces antiviral therapies used in the treatment and prevention of HIV and hepatitis B and C, as well as oncology and cell therapy treatments. Its products are purchased by pharmacies, hospitals, wholesale distributors, and healthcare providers. Its shares trade on NASDAQ under the ticker GILD.
What is Gilead Sciences, Inc.'s net worth?
Gilead Sciences, Inc. has a market value (market cap) of $186.5B at the latest share price, and shareholders' equity of $11.8B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Gilead Sciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $3.2B on revenue of $30.5B.
How much revenue does Gilead Sciences, Inc. make?
Over the twelve months to June 30, 2026 Gilead Sciences, Inc. reported revenue of $30.5B. That is 5.5% more than a year earlier.
When did Gilead Sciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 2, 2026.
When is Gilead Sciences, Inc.'s next earnings report?
Gilead Sciences, Inc.'s next report is expected around October 29, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Does Gilead Sciences, Inc. pay a dividend?
Yes. Gilead Sciences, Inc. declared dividends of $3.16 per share in fiscal 2025, a yield of 2.10% at the current price.
Similar companies
Compare GILD with
Follow GILD
Get an email when Gilead Sciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Gilead Sciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.